News

Asarina Pharma Annual Report for 2019 released

(Stockholm April 14, 2020) Asarina Pharma AB today announces that its Annual Report for 2019 is now available on the company’s website.

Full PDF

NOTICE OF ANNUAL GENERAL MEETING IN asarina pharma AB (publ)

The shareholders of Asarina Pharma AB (publ) (the “Company”) are hereby summoned to attend the Annual General Meeting (“AGM”) on 5 May 2020, at 10.00 CEST at Erik Penser Bank, Apelbergsgatan 27 in Stockholm, Sweden. Registration starts at 09.30 CEST and will stop when the meeting starts. NOTE: This is an unofficial translation of the…

Full PDF

Asarina Pharma to release historic Phase IIb PMDD data on schedule

Asarina Pharma expects to release top-line results of its Phase IIb PMDD study on schedule at the end of April. Asarina Pharma’s other studies on menstrual migraine and Tourette syndrome also remain on track. The company’s digital R&D Day, on March 26, will detail four key metrics it will use to evaluate the efficacy of…

Full PDF

Asarina Pharma R&D Day 2020 to go digital

Asarina Pharma’s March 26 R&D day will now be streamed live via digital link due to Coronavirus restrictions. The event focuses on preparing for the upcoming study results in the company's leading indication PMDD, and will still include presentations from PMDD practitioners, patients and leading researchers. Asarina Pharma will also host a study results presentation…

Full PDF

Invitation to Asarina Pharma R&D Day 2020

Asarina Pharma invites institutional investors, financial analysts and media to join its R&D day, focused on the upcoming Study results in the company's lead indication PMDD.

Full PDF